PRELIMINARY IMAGING RESULTS USING IN-111 LABELED CYT-356 (PROSTASCINT(TM)) IN THE DETECTION OF RECURRENT PROSTATE-CANCER

To evaluate whether In-111 capromab pendetide (an antibody conjugate d irected to a glycoprotein found primarily on the cell membrane of pros tate tissue) radioimmunoscintigraphy can localize residual or metastat ic prostatic carcinoma in 15 patients after prostatectomy and lymphade nectomy for prostatic carcinoma with rising serum prostate-specific an tigen. One patient with 0.6 ng/ml serum prostate-specific antigen had normal imaging results and 14 patients had scintigraphic evidence of r esidual prostatic bed or metastatic prostatic carcinoma. Two patients with borderline abnormal bone scans had abnormal activity in the same regions on In-111 capromab pendetide images. All patients had negative radiographic abdominal and pelvic cross-sectional prestudy images, an d there were no adverse effects related to In-111 capromab pendetide i nfusion and little human antimouse antibody response.